Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cisplatin exposed MCF10A and HepG2 clones and untreated controls

ABSTRACT: In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors

PROVIDER: PRJEB21971 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR2313901_1.fastq.gz	Fastqsanger.gz
	ERR2313901_2.fastq.gz	Fastqsanger.gz
	ERR2313902_1.fastq.gz	Fastqsanger.gz
	ERR2313902_2.fastq.gz	Fastqsanger.gz
	ERR2313903_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 26

Similar Datasets

Nitrosamine exposed HepG2 clones

Project description:Mutational signature of nitrosamines in HepG2

| PRJEB36272 | ENA

Expression data of untreated or cisplatin-treated wildtype or Rb-/- MEFs

Project description:The absence of the Rb tumor suppressor gene changes levels/activities of transcription factors (e.g., E2F and p53) which alter gene expression patterns, related to cell cycle control and cellular response to DNA damage. Cisplatin is a genotoxic chemotherapeutic agent and wildtype or Rb null cells have different sensitivities to cisplatin-induced cytotoxicity. We used microarrays to compare global profiles of gene expression and distinct responses of wildtype and Rb null MEFs in response to cisplatin. Keywords: genotype and cisplatin treatment

2007-09-01 | GSE6206 | GEO

Different gene expression in cisplatin chemo-resistant or sensitive of esophageal squamous carcinoma patients.

Project description:To investigate mRNA expression difference in cisplatin chemo-sensitivity in esophageal squamous carcinoma patients. We performed gene expression profiling analysis using data obtained from RNA-seq of 6 different patients.

2023-05-01 | GSE229974 | GEO

Mutational signature of AA1 in MCF10A and HepG2

Project description:Mutational signature of AA1 in MCF10A and HepG2

| PRJEB36497 | ENA

Expression Profiles of HepG2 cells treated with 7M-BM-5M of the genotoxic compound cisplatin

Project description:The transcriptomic changes induced in the human liver cell line HepG2 by 7M-BM-5M of cisplatin after treatment for 12, 24 and 48h The study investigated differential gene expression in HepG2 cell line mRNA following 12,24 and 48 hours of exposure to 7M-BM-5M of cisplatin and its solvent. Three biological replicates per compound/solvent. In total 18 arrays .

2013-12-05 | E-GEOD-38122 | biostudies-arrayexpress

Transcription profiling of rat kidney exposed to different doses of Cisplatin- ILSI-HESI NephroToxicity Study - Cisplatin

Project description:Evaluation and comparison of biological responses of rats and gene expression responses of the kidney in rats exposed to different doses of Cisplatin [CAS:15663-27-1;CHEBI:27899]

2007-01-10 | E-TOXM-11 | biostudies-arrayexpress

Gene expression data from human NSCLC U1810 residual clones 9 days after a one-hour pulse treatment with cisplatin

Project description:Background: The platinum compounds cisplatin and carboplatin are the mainstay of chemotherapy for lung cancer; however, treatment failure remains a critical issue since about 60% of all non-small cell lung cancer (NSCLC) patients display intrinsic platinum resistance. Methods: We analyzed global gene expression profiles in NSCLC clones surviving a pulse treatment with cisplatin by microarray and mapped deregulated signaling networks in silico by Ingenuity Pathway Analysis (IPA). Results: Cisplatin-surviving NSCLC clones were demonstrated to have heterogeneous gene expression patterns both in terms of the number and the identity of the altered genes. Genes involved in Wnt signaling pathway (DKK1), DNA repair machinery (XRCC2) and cell-cell/ cell-matrix interaction (FMN1 and LGALS9) were among the top deregulated genes by microarray and were subsequently validated by q-RT-PCR. We focused on DKK1, which was previously reported to be overexpressed in NSCLC. IPA network analysis revealed coordinate up-regulation of several DKK1 transcriptional regulators (TCF4, EZH2, DNAJB6 and HDAC2) in cisplatin-surviving clones. Knockdown of DKK1 by siRNA sensitized untreated NSCLC cells to cisplatin, illustrating a putative role of DKK1 in intrinsic platinum resistance. Conclusions: Gene expression analysis identified DKK1 as a putative cisplatin resistance marker and a potential novel therapeutic target to overcome platinum resistance in NSCLC. U1810 cells were sparsely seeded for clonogenic survival assay in three separate experiments (replicate 1-3), left untreated or treated with cisplatin for 1 h and then kept for 9 days to assay long-term effects of a single pulse treatment.

2014-04-04 | E-GEOD-48244 | biostudies-arrayexpress

Basal mRNA expression levels of single-cell derived FaDu clones with cisplatin-sensitive / resistant phenotype

Project description:The extent of intratumoral heterogeneity, the subclonal structures and the mechanisms of treatment-induced clonal selection by cisplatin was investigated in the squamous cell carcinoma cell line model FaDu. We picked 96 single cell-derived clones from the cisplatin-sensitive parental FaDu cell line. After expansion as separate cultures, these clones were tested for their sensitivity to CDDP. By this approach, we isolated individual cell clones that were primarily resistant (clones 5 & 78) and others that showed high sensitivity to CDDP (clones 46 & 54). Basal mRNA expression levels associated with CDDP sensitivity / resistance were determined in two independent microarray analyses.

2017-12-04 | E-MTAB-6022 | biostudies-arrayexpress

Gene expression data from human NSCLC U1810 residual clones 9 days after a one-hour pulse treatment with cisplatin

2014-04-04 | GSE48244 | GEO

Gene expression profiling and the effect of HDAC9 in cisplatin resistance of esophageal squamous cell carcinoma

Project description:Esophageal cancer is one of the most serious health problems globally because of its high incidence and mortality rate. Cisplatin (CDDP) is the primary treatment but limited by the drug resistance. However, the mechanism of cisplatin resistance remains unclear. Herein, the CDDP-resistant cell line TE-1/CDDP was established to compared with TE-1, the expression profiles of circRNAs mRNA and lncRNA were compared between TE-1/CDDP and TE-1 using microarray analysis, and used this as a basis for exploring possible mechanisms of drug resistance in genes such as HDAC9.

2023-09-14 | GSE242834 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data